Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
|
Sep 2012
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
Molecular Testing in Patients with Suspected Myelodysplastic Syndromes
|
Oct 2016
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
Palliative and End-of-Life Care in Myelodysplastic Syndromes
|
Oct 2016
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times
|
Aug 2017
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
Assessing Quality of Care for the Myelodysplastic Syndromes
|
Aug 2016
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes.
|
Aug 2013
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
|
Sep 2017
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).
|
Jan 2014
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
Standardizing the Initial Evaluation for Myelodysplastic Syndromes.
|
Nov 2013
|
Curr Hematol
|
myelodysplastic syndromes (MDS)
|
Stem Cell Transplant from Unrelated Donor in Patients with Severe Aplastic Anemia: Indications, Donor Selection, Conditioning, GVHD Prophylaxis
|
Feb 2015
|
Curr Drug Targets
|
aplastic anemia
|